Interpretation 2171
Tier 1|
|
|
Variants
Primary Sites
Tumor Types
Interpretation
Vemurafenib Dabrafenib Dabrafenib + Trametinib
Citations
- Flaherty KT, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367(2):107-14
- Planchard D, et al. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol 2016;17(5):642-50
- Flaherty KT, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363(9):809-19
- Gautschi O, et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 2012;7(10):e23-4
Last updated: 2018-04-06 15:16:54 UTC